Class III Additional Registration Requirements

1. Key takeaways

Acuerdo No. 0631-ARSA-2023, the Reglamento para el Control Sanitario de Dispositivos Médicos y otros Dispositivos de Interés Sanitario, provides in Article 46 that the dossier for Class III devices consists of the items listed in Articles 43, 44 and 45 plus four additions: 1 devices manufactured from human or animal tissues and their derivatives must submit a manufacturing summary; 2 certified testing for biocompatibility, stability, cytotoxicity and electrical safety; 3 a finished product analysis certificate or its equivalent document, stating the final documented conclusion according to the device type; 4 where the documents required by risk classification cannot be submitted, five categories of equivalent documents are accepted: the free sale certificate or its equivalent; the manufacturer’s BPM certificate or its equivalent; the device CE certificate issued by a European Union notified body (93/42/CEE); the declaration of good manufacturing practice conformity stated in the free sale certificate (issued by the health authority or the corresponding ministry); and the IVD CE certificate issued by a European Union notified body (98/79/EC). The GRZAN regulatory team notes: the equivalent documents of Article 46, item 4, are a substitute for when submission is not feasible, not routine material; submitting them as routine material will instead be read as the primary document being missing.

2. Legal basis

The table below maps each requirement of Article 46 to its provision and key point.

3. Expert insights

Insight 1: the four tests must be certified (certificadas). Article 46, item 3, uses the words pruebas certificadas, not reports. This raises the bar for who may issue the test reports and in what form — they should come from qualified laboratories and be traceable. The GRZAN regulatory team recommends scheduling the four tests first: the Class III testing cycle is often longer than the six-month window of the risk classification report, and a late start will force reliance on extensions or even reclassification.

Insight 2: Article 46, item 4, asks for a final documented conclusion, not raw data. The provision requires the finished product analysis certificate or its equivalent document to indicate the final documented conclusion according to the type of medical device (indique el dictamen final documentado de acuerdo al tipo de dispositivo médico). Unlike Article 45, which asks for standards, Class III requires a conclusive document addressed to the device type. Submitting raw test data without a conclusion is a non-conformity.

Insight 3: the trigger for the five equivalent documents is inability to submit. Article 46, item 5, opens with the words en casos en los que no sea factible presentar un documento que cumpla con los requisitos establecidos — in cases where it is not feasible to present a document meeting the established requirements. This is a conditional substitution mechanism, activated only when the prescribed document cannot objectively be obtained. Filing it as routine material is, in practice, an admission that the primary document is missing.

Insight 4: in Honduras the CE certificate is an equivalent document, not a market access prerequisite. The provision lists both the device CE certificate (93/42/CEE) and the IVD CE certificate (98/79/EC) within the equivalent documents list. This echoes Article 3, Section I, which keeps both abbreviations CE and CEE: in Honduras, CE is evidence on an alternative route, not a mandatory condition. Companies should neither treat holding CE as a reason to skip testing, nor treat lacking CE as a reason they cannot apply.

Insight 5: the renewal stage repeats the same supplementary requirements. Items 11 a) to e) of the renewal list in the final paragraph of Article 46 correspond exactly to item 5, listing the same five categories of equivalent documents. This shows that the Class III additions are identical at first registration and at renewal — renewal is not a simplified process; companies should keep the four test categories valid continuously after registration.

4. Practical recommendations

• Start the four tests at the very beginning of a Class III project, no later than issuance of the risk classification report.
• Ensure the finished product analysis certificate states the final documented conclusion for the device type, not raw data alone.
• Use the five equivalent documents only when the prescribed documents cannot objectively be submitted, and state the reason.
• Do not treat CE certificates as routine material or as a reason to skip testing; submit them only in equivalent-document scenarios.
• At renewal, prepare the same supplementary documents under item 11 of the final paragraph of Article 46; do not treat renewal as simplified.
• Maintain the validity of the four tests continuously after registration to avoid last-minute retesting before renewal.

5. Verification checklist

• □ The four tests were started before issuance of the risk classification report
• □ The finished product analysis certificate states the final documented conclusion for the device type
• □ Equivalent documents were used only when submission was not feasible, with the reason stated
• □ CE certificates were not submitted as routine material or as a testing exemption
• □ Renewal supplementary documents were prepared under item 11 of the final paragraph of Article 46
• □ A maintenance mechanism keeps the four tests valid after registration

Related reading: [Article 23 — Class IIB device-specific ISO standards](/honduras-medical-device-registration/class-iib-device-specific-iso-standards/) | [Article 25 — The twelve renewal dossier items](/honduras-medical-device-registration/renewal-dossier-twelve-items/) | [Article 13 — The six-month risk classification report](/honduras-medical-device-registration/risk-classification-report-six-months/)

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Honduran market. Our team manages Secretariat of Health (SESAL) registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com